Search

Your search keyword '"Volkan Hazar"' showing total 2 results
Start Over Author "Volkan Hazar" Publisher galenos yayinevi
2 results on '"Volkan Hazar"'

1. Utility of Procalcitonin in the Engraftment Phase of Hematopoietic Stem Cell Transplantation in Children

Author

Koray Yalçın, Dayanat Pashayev, Suna Çelen, Suleimen Zhumatayev, Gülsün Karasu, Vedat Uygun, Volkan Hazar, and Akif Yeşilipek

Subjects
engraftment, hematopoetic stem cell transplantation, procalcitonin, Medicine, Pediatrics, RJ1-570
Abstract

Aim:In hematopoietic stem cell transplantation (HSCT), the phase of engraftment which can be described as an “immunogenic storm”, is also vulnerable to infections and it has been always very hard to discriminate the cause of fever in this special period of HSCT. In this study, we aim to determine if procalcitonin (PCT) could be used to define the cause of fever in the engraftment phase of HSCT.Materials and Methods:This study involves 81 patients who consecutively underwent allogeneic HSCT between October 2017-June 2020 in our pediatric HSCT unit. The patients were divided into two groups due to the origin of the fever during engraftment as infectious fever group (n=42) and the non-infectious fever group (n=39).Results:The median duration of fever for all groups was 4 days (1-11 days) and it was significantly lower in the non-infectious fever group compared to the infectious fever group (3 vs. 4 respectively p=0.001). The median PCT levels was 0.6 ng/mL (0.04-83) for all groups and it was significantly higher in the infectious fever group compared to non-infectious (1.4 vs. 0.3 p

Published
2022
Full Text
View/download PDF

2. Hematopoietic Stem Cell Transplantation Activity and Trends at a Pediatric Transplantation Center in Turkey During 1998-2008

Author

Vedat Uygun, Akif Yesilipek, Volkan Hazar, Mediha Akcan, Gulsun Karasu, and Alphan Kupesiz

Subjects
medicine.medical_specialty, lcsh:Internal medicine, Turkey, Transplant-related mortality, medicine.medical_treatment, chemical and pharmacologic phenomena, Hematopoietic stem cell transplantation, immune system diseases, Neuroblastoma, Internal medicine, hemic and lymphatic diseases, medicine, lcsh:RC31-1245, Pediatric, business.industry, lcsh:RC633-647.5, Hematology, Transplant-Related Mortality, lcsh:Diseases of the blood and blood-forming organs, medicine.disease, Surgery, Transplantation, Haematopoiesis, Hemoglobinopathy, surgical procedures, operative, Cord blood, Stem cell, business, therapeutics, Research Article
Abstract

Objective: The aim of this study was to document hematopoietic stem cell transplantation (HSCT) activity and trends at our treatment center. Material and Methods: Data collected over a 10-year period were retrospectively analyzed, concentrating primarily on types of HSCT, transplant-related mortality (TRM), stem cell sources, indications for HSCT, and causes of death following HSCT. Results: In total, 222 allogeneic (allo)-HSCT (87.4%) and 32 autologous (auto)-HSCT (12.6%) procedures were performed between 1998 and 2008. Stem cells obtained from unrelated donors were used in 22.6% (50/222) of the allo- HSCTs. Cord blood was the source of hematopoietic stem cells (HSC) in 12.2% of all transplants. The most common indication for allo-HSCT was hemoglobinopathy (43.2%), versus neuroblastoma (53.1%) for auto-HSCT. The TRM rate 1 year post transplantation was 18.3% ± 2.5% for all transplants, but differed according to transplantation type (23.5% ± 7.9% for auto-HSCT and 17.5% ± 2.6% for allo-HSCT). The most common cause of death 1 year post HSCT was infection (35.9%). Conclusion: The TRM rate in the patients that underwent allo-HSCT was similar to that which has been previously reported; however, the TRM rate in the patients that underwent auto-HSCT was higher than previously reported in developed countries. The selection of these patients to be transplanted must be made attentively.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results